EXtendedAnalysis for Cancer Treatment

Inclusion Criteria: Consenting patients of \>19 years with advanced cancer fulfilling the criteria of having: * an advanced malignancy with metastatic spread refractory to conventional treatment * a life expectancy of \>4 months, * the possibility to access and biopsy tumour material within 4 weeks before onset of individualized treatment, * a malignancy amenable to further treatment options with either cytotoxic drugs, tyrosine kinase inhibitors, monoclonal antibodies or related molecules with anti-proliferative potential to cancer cells, as assessed by the ex vivo analysis and a likelihood of treatment response according to the mathematical model (all outlined in detail above), * agreed to participate by their signature on an informed consent form are eligible. Exclusion Criteria: * Presence of further treatment options, as defined by NCCN guidelines which are available in Austria representing a possible further treatment-related response by conventional therapies according to generally accepted medical evidence. * No fresh and viable tumor material available. * Current use of therapeutic warfarin. * Unresolved toxicity of National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (NCI CTCAE v4.0) Grade 2 or higher from previous anti-cancer therapy, except alopecia. * Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs. * A history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection. * A history of known glucose-6-phosphate dehydrogenase (G6PD) deficiency. * History of other malignancy. Subjects who have been disease-free for 5 years or those with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible. * Uncontrolled medical conditions (i.e, diabetes mellitus, hypertension, etc), psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol) * unwillingness or inability to follow the procedures required in the protocol. * pregnant or lactating females. * History of alcohol or drug abuse within 6 months prior to screening. * No informed consent available.